Intelligent Medical Devices C. difficile Assay: Next Steps?

Tuesday, November 29, 2011 - 6:30pm

Clostridium difficile is a bacterium that causes severe diarrhea through disruption of normal intestinal flora in the gut.   This bacterium contributes to one of the leading causes of hospital acquired infections affecting over 300,000 patients in Canada each year.  Of these patients, 5% have severe disease leading to colectomy, intensive care, or death.  Furthermore, upon outbreaks, incidence rates can increase up to 5 times.  In order to reduce incidence rates and to prevent a future outbreak, hospitals invest heavily in infection control and the timely diagnosis of patients.  In recent years, the introduction of PCR diagnostic assays for C. difficile testing has become a more effective approach compared to its incumbents. Higher costs, however, have limited its adoption as a sole diagnostic.

Intelligent Medical Devices (IMDx) along with Abbott Molecular have developed a C. difficile PCR diagnostic assay that is automated, high capacity and accurate. Currently bearing a CE mark, it awaits the approval in Canada and the US. Upon approval, the major barrier to adoption is the high capital investment required in order to implement the IMDx C. difficile assay. This presentation will propose a pilot model to demonstrate the savings to hospitals through the adoption of IMDx C. difficile assay in a hospital-networked hub while increasing the sales for IMDx and Abbott’s products.  This presentation also serves to outline many of the characteristic and concerns of C. difficile associated disease and various diagnostics currently on market.

Ingenia
Presented by Team Ingenia. (Aditya Rana, Dana Novotny, Tina Luu, Tejashree Chaugule, Ashton Jagdeo)

 

Tuesday, November 29, 2011, 6:30-7:30pm
University of Toronto Mississauga
Instructional Building, Room 335